EVEROLIMUS — all Canadian products
28 DINs
26 marketed/approved
0 in shortage
Every Health Canada Drug Identification Number whose active ingredient is EVEROLIMUS, with holder, form, strength and current status, compared weekly against the Drug Product Database.
| DIN | Product | Company | Form | Route | Strength | Status | Shortage |
|---|---|---|---|---|---|---|---|
| 02339501 | AFINITOR | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | Oral | EVEROLIMUS 5 MG | Marketed | |
| 02339528 | AFINITOR | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | Oral | EVEROLIMUS 10 MG | Marketed | |
| 02369257 | AFINITOR | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | Oral | EVEROLIMUS 2.5 MG | Marketed | |
| 02425661 | AFINITOR DISPERZ | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet For Suspension | Oral | EVEROLIMUS 5 MG | Marketed | |
| 02425645 | AFINITOR DISPERZ | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet For Suspension | Oral | EVEROLIMUS 2 MG | Marketed | |
| 02425653 | AFINITOR DISPERZ | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet For Suspension | Oral | EVEROLIMUS 3 MG | Marketed | |
| 02375907 | CERTICAN | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | Oral | EVEROLIMUS 0.25 MG | Approved | |
| 02375915 | CERTICAN | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | Oral | EVEROLIMUS 0.5 MG | Approved | |
| 02375923 | CERTICAN | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | Oral | EVEROLIMUS 0.75 MG | Approved | |
| 02530104 | NAT-EVEROLIMUS | NATCO PHARMA (CANADA) INC | Tablet | Oral | EVEROLIMUS 5 MG | Marketed | |
| 02530120 | NAT-EVEROLIMUS | NATCO PHARMA (CANADA) INC | Tablet | Oral | EVEROLIMUS 10 MG | Marketed | |
| 02530112 | NAT-EVEROLIMUS | NATCO PHARMA (CANADA) INC | Tablet | Oral | EVEROLIMUS 7.5 MG | Approved | |
| 02530090 | NAT-EVEROLIMUS | NATCO PHARMA (CANADA) INC | Tablet | Oral | EVEROLIMUS 2.5 MG | Marketed | |
| 02504685 | PMS-EVEROLIMUS | PHARMASCIENCE INC | Tablet | Oral | EVEROLIMUS 5 MG | Marketed | |
| 02504693 | PMS-EVEROLIMUS | PHARMASCIENCE INC | Tablet | Oral | EVEROLIMUS 10 MG | Marketed | |
| 02504677 | PMS-EVEROLIMUS | PHARMASCIENCE INC | Tablet | Oral | EVEROLIMUS 2.5 MG | Marketed | |
| 02532433 | REDDY-EVEROLIMUS | DR REDDY'S LABORATORIES LTD | Tablet | Oral | EVEROLIMUS 10 MG | Marketed | |
| 02532409 | REDDY-EVEROLIMUS | DR REDDY'S LABORATORIES LTD | Tablet | Oral | EVEROLIMUS 2.5 MG | Marketed | |
| 02532417 | REDDY-EVEROLIMUS | DR REDDY'S LABORATORIES LTD | Tablet | Oral | EVEROLIMUS 5 MG | Marketed | |
| 02532425 | REDDY-EVEROLIMUS | DR REDDY'S LABORATORIES LTD | Tablet | Oral | EVEROLIMUS 7.5 MG | Approved | |
| 02492911 | SANDOZ EVEROLIMUS | SANDOZ CANADA INCORPORATED | Tablet | Oral | EVEROLIMUS 2.5 MG | Marketed | |
| 02492938 | SANDOZ EVEROLIMUS | SANDOZ CANADA INCORPORATED | Tablet | Oral | EVEROLIMUS 5 MG | Marketed | |
| 02492946 | SANDOZ EVEROLIMUS | SANDOZ CANADA INCORPORATED | Tablet | Oral | EVEROLIMUS 10 MG | Marketed | |
| 02463253 | TEVA-EVEROLIMUS | TEVA CANADA LIMITED | Tablet | Oral | EVEROLIMUS 10 MG | Marketed | |
| 02463237 | TEVA-EVEROLIMUS | TEVA CANADA LIMITED | Tablet | Oral | EVEROLIMUS 5 MG | Marketed | |
| 02463229 | TEVA-EVEROLIMUS | TEVA CANADA LIMITED | Tablet | Oral | EVEROLIMUS 2.5 MG | Marketed | |
| 02450267 | AFINITOR | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | Oral | EVEROLIMUS 7.5 MG | Cancelled Post Market | |
| 02463245 | TEVA-EVEROLIMUS | TEVA CANADA LIMITED | Tablet | Oral | EVEROLIMUS 7.5 MG | Cancelled Pre Market |
Browse other molecules: